However, no relationship with anti-cyclic citrullinated peptide antibodies (ACPA) status, ILD and CTD duration, and biologic disease-modifying anti-rheumatic drugs (bDMARDs) was found in RA-ILD+ patients for any of the proteins evaluated (MMP-2, MMP-7, MMP-9, MMP-10, MMP-12, and TIMP-1) (data not shown). This evidence concerns the gene MMP2 and interstitial lung disease.